Therefore, the timing of intervention in subsequent clinical trials examining TNF-α neutralization in acute pancreatitis should be closely related to changes in TNF-α serum levels, and inclusion and exclusion criteria should be carefully defined to identify the population most likely to benefit from such treatment [49]. This evidence concerns the gene TNF and acute pancreatitis.